The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient's NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CDI23+Leukemic Stem and Progenitor Cells in AML and MDS

被引：0
|
作者：
Schmitt, Nanni [1 ]
Siegler, Jana-Julia [2 ]
Beck, Alexandra [1 ]
Hoppe, Lea [1 ]
Abba, Mohammed [1 ]
Streuer, Alexander [1 ]
Klein, Stefan [1 ]
Hofmann, Wolf-Karsten [1 ]
Merz, Christian [2 ]
Pahl, Jens [2 ]
Nowak, Daniel [1 ]
机构：
[1] Heidelberg Univ, Med Fac Mannheim, Dept Hematol & Oncol, Mannheim, Germany
[2] Affimed GmbH, Mannheim, Germany
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210275
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4143 / 4143
页数：1
相关论文
共 6 条
  • [1] The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+Leukemic Stem- and Progenitor Cells in AML
    Schmitt, Nanni
    Siegler, Jana-Julia
    Wagner, Lena
    Schulze, Nicole
    Beck, Alexandra
    Hofmann, Wolf-Karsten
    Haneke, Torsten
    Reusch, Uwe
    Medina-Echeverz, Jose
    Endell, Jan
    Ross, Thorsten
    Merz, Christian
    Nowak, Daniel
    BLOOD, 2022, 140 : 8815 - 8816
  • [2] Novel bispecific innate cell engager AFM28 efficiently directs allogenic NK cells to CD123+leukemic blasts and stem cells in acute myeloid leukemia and myelodysplastic neoplasms
    Schmitt, N.
    Siegler, J. -J
    Pahl, J.
    Wagner, L.
    Schulze, N.
    Beck, A.
    Haneke, T.
    Reusch, U.
    Medina-Echeverz, J.
    Endell, J.
    Hofmann, W-K
    Ross, T.
    Nowak, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 100 - 101
  • [3] AFM28, a Novel Bispecific Innate Cell Engager (ICE ®), Designed to Selectively Re-Direct NK Cell Lysis to CD123+Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Goetz, Jana-Julia
    Pahl, Jens
    Schmitt, Nanni
    Mueller, Thomas
    Haneke, Torsten
    Kozlowska, Izabela
    Sarlang, Séverine
    Knackmuss, Stefan
    Peters, Eike
    Reusch, Uwe
    Ross, Thorsten
    Nowak, Daniel
    Hofmann, Wolf-Karsten
    Merz, Christian
    BLOOD, 2021, 138
  • [4] Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study
    Champlin, Richard
    Lee, Dean A.
    Fernandez-Vina, Marcelo
    Rondon, Gabriela
    McAdams, Patricia
    Juianne, Chen
    Qazilbash, Muzaffar H.
    Kebriaei, Partow
    Parmar, Simrit
    Shpall, Elizabeth J.
    Popat, Uday
    Alousi, Amin
    Ciurea, Stefan O.
    Cooper, Laurence
    Peter, Thall
    McMannis, John
    BLOOD, 2010, 116 (21) : 217 - 217
  • [5] PRE-CLINICAL MODELS OF ACUTE MYELOID LEUKEMIA DEMONSTRATE AFM28 EFFICIENTLY DIRECTS ALLOGENEIC NK CELLS TO CD123+LEUKEMIC BLASTS AND STEM CELLS
    Siegler, Jana-Julia
    Schmitt, Nanni
    Wagner, Lena
    Schulze, Nicole
    Beck, Alexandra
    Hofmann, Wolf-Karsten
    Haneke, Torsten
    Reusch, Uwe
    Medina-Echeverz, Jose
    Ross, Thorsten
    Merz, Christian
    Nowak, Daniel
    Endell, Jan
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 120 - 121
  • [6] NKX101, an allogeneic off-the-shelf NKG2D CAR-NK cell therapy, has potent in vitro cytotoxicity against patient-derived AML leukemic stem cells and non-leukemic stem cell blasts
    Hansen, Kyle
    Cho, Cynthia
    Kothari, Nishi
    Shook, David
    Trager, James
    CANCER RESEARCH, 2024, 84 (06)
1